PALM BEACH, Florida, July 11, 2017 /PRNewswire/ --
The healthcaresector one was of the better performing sectors in the second quarter and appears to be not far behind the tech sector looking at the year-to-date performance. Healthcare stocks continue to rally upon expectations of a favorable policy environment. The
Medical Innovation Holdings, Inc. (OTC: MIHI) News: MIHI Enters Into a Definitive Purchase Agreement to Acquire Health and Lifestyle Supplements Company Designed for Better Living, Healthier and Longer Life - Medical Innovation Holdings today announced that they have reached a Definitive Agreement with Renaissance Health Publishing, LLC (RHP) and its wholly-owned subsidiaries (http://www.renownhealthproducts.com ). Renaissance is a Florida-based nutraceutical company and under this agreement, MIHI will acquire 100% of the assets of the company in a cash and stock transaction valued between $2.5 to $3.5 million dollars. The Company will provide a proprietary product line with specialized formulations along with Trademarked product names. Along with the acquisition of the company and its wholly-owned subsidiaries, MIHI will receive top and bottom-line revenue growth, robust customer base, existing staff and management, and certain marketing materials designed to promote the Renaissance product line. Read this and more news for MIHI at http://www.marketnewsupdates.com/news/mihi.html
Renaissance is a nationally-known research and development company recognized for its portfolio of best-in-class, physician-developed, natural-health supplements designed to provide their customers with a better, healthier, and longer life. For over 16 years, Renaissance has used, and continues to use, the highest quality and concentration of powerful ingredients to create products that are naturally safe and proven to be effective. As a socially-responsible company, they do not perform any animal testing during any of its research and development.
Arturo "Jake" Sanchez, MIHI CEO and Director, stated: "This is the first of many more acquisition agreements to come. We will use RHP as a platform company to acquire additional supplement-based companies to add additional product lines. We are also benefiting our network of physician providers by increasing their access to readily available alternative sources to treat their patients while increasing the practice's revenues. Under this agreement, we are giving the medical providers the opportunity to provide the best care for their patients by incorporating the latest advances in alternative nutraceuticals into their practice versus harmful and many times unresponsive pharma developed medicines."
In other Healthcare market activity of note from trading on yesterday:
Xtant Medical Holdings, Inc. (NYSE: XTNT) closed up over 30% with strong trading volume on Monday reaching over 8.5 million shares traded by the market close. Xtant Medical Holdings develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) closed up over 12% at $3.15 on Monday with over 23 million shares traded on the day. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and pulmonary arterial hypertension (PAH).
Amarin Corporation plc (NASDAQ: AMRN) closed up on Monday at $4.15 with over 3 million shares traded by the market close. Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a highly-pure, omega-3 fatty acid product available by prescription.
CareDx, Inc. (NASDAQ: CDNA) closed up over 25% on Monday at $1.60 with over 6.59 million shares traded by the market close. CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press releases issued by Medical Innovation Holdings, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information: Media Contact email: firstname.lastname@example.org +1(561)325-8757
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All